Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Asieris Pharma Partners with SPH Keyuan to Commercialize Cevira – World’s First Non‑Surgical Cervical Precancer Treatment Launches in China

Fineline Cube Mar 25, 2026
Company Deals

Sciwind Biosciences Files Hong Kong IPO Prospectus – GLP‑1 Obesity Pipeline Targets R&D Funding for Weight Management Franchise

Fineline Cube Mar 25, 2026
Company Deals

Kali Therapeutics Licenses KT501 to Sanofi – $1.23B Deal for Trispecific T-Cell Engager Targets Autoimmune Diseases

Fineline Cube Mar 24, 2026
Company Deals Drug

Belief BioMed Partners with Grand Life Sciences on BBM-H803 – AAV Gene Therapy for Hemophilia A Targets Greater China Market

Fineline Cube Mar 24, 2026
Company Deals

Hanmi Pharmaceutical Partners with Chongqing Zhongfu – Amlodipine/Losartan Fixed-Dose Combo Targets China Out-of-Hospital Digital Market

Fineline Cube Mar 24, 2026
Policy / Regulatory

China NHC Elevates Chikungunya and SFTS to Category B Status – Enhanced Surveillance and Control Measures Effective April 2026

Fineline Cube Mar 25, 2026
Company Drug

Zhifei Bio Initiates Phase I Study for DTaP-Hib Quadrivalent Vaccine – Component Combination Targets Pediatric Immunization Compliance

Fineline Cube Mar 25, 2026
Company Drug

Changchun High-Tech Wins FDA Orphan Drug Designation for GenSci128 – TP53 Y220C Reactivator Targets Gastric Cancer

Fineline Cube Mar 25, 2026
Company Drug

Ocumension Therapeutics Gains CDE Approval for Phase III Presbyopia Trial

Fineline Cube Jun 11, 2025

Ocumension Therapeutics (HKG: 1477), a Chinese ophthalmology specialist, announced that the Center for Drug Evaluation...

Company Deals

Jiangxi Rimag Plans Acquisition of Changsha Zhongya Medical for RMB 29.5 Million

Fineline Cube Jun 10, 2025

China-based Jiangxi Rimag Group Co., Ltd (HKG: 2522) announced plans to acquire 100% stake in...

Company Drug

Biogen Launches Qalsody in China for SOD1-ALS Treatment

Fineline Cube Jun 10, 2025

US-based Biogen (NASDAQ: BIIB) officially launched Qalsody (tofersen) in China this week. The drug, the...

Company Deals

Boehringer Ingelheim and Echosens Expand Partnership to Tackle MASH

Fineline Cube Jun 10, 2025

Germany-based Boehringer Ingelheim and France-based Echosens have expanded their partnership to enhance early screening, precise...

Others

China Expands Medical Insurance Coverage in New State Council Guidelines

Fineline Cube Jun 10, 2025

The General Office of the State Council released the “Guidelines on Further Safeguarding and Improving...

Company

WuXi Biologics Commences Construction on Microbial Production Base in Chengdu

Fineline Cube Jun 10, 2025

China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) announced the official...

Company Drug

Sihuan Pharma’s Xuanyuening Granted New Indication Review in China

Fineline Cube Jun 10, 2025

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that the National Medical Products Administration...

Company Drug

Johnson & Johnson Launches Tremfya IV in China for Inflammatory Bowel Diseases

Fineline Cube Jun 10, 2025

US-based Johnson & Johnson (J&J; NYSE: JNJ) announced the commercial launch of Tremfya (guselkumab) intravenous...

Company Deals

Deep Surgery Secures Pre-Series A Funding for Microsurgery Robot Expansion

Fineline Cube Jun 10, 2025

Guangzhou-based microsurgery robot developer Deep Surgery has secured “tens of millions” of renminbi in a...

Company

ImmuneOnco Appoints Zhuli Wu as Chief Medical Officer to Lead Clinical Strategy

Fineline Cube Jun 10, 2025

China-based ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) announced the appointment of Zhuli Wu as...

Company Drug

Hengrui Pharmaceuticals Launches Aiweida for HER2-Mutated NSCLC in China

Fineline Cube Jun 10, 2025

China’s Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced the first commercial shipment of its...

Company Medical Device

Suzhou Sinus Medtech Wins FDA Breakthrough Designation for oHCM Ablation System

Fineline Cube Jun 10, 2025

Suzhou Sinus Medical Technologies Co., Ltd., a China-based medical device innovator, announced that its in-house...

Company Drug

Novartis’ PSMAddition Trial Yields Positive Results for Pluvicto in mHSPC

Fineline Cube Jun 10, 2025

Swiss pharmaceutical giant Novartis (NYSE: NVS) announced the interim results from its Phase III PSMAddition...

Company Drug

Innovent Biologics’ Xinbiyue Approved for Macau Market

Fineline Cube Jun 10, 2025

China-based Innovent Biologics Inc. (HKG: 1801) announced that it has received market approval from the...

Company Deals

Innogen Pharma Resubmits Hong Kong IPO Application With Promising Diabetes Drug

Fineline Cube Jun 10, 2025

China-based Guangzhou Innogen Pharmaceutical Group Co., Ltd. has resubmitted its application for a main board...

Company Deals

Harrow Signs Licensing Deal for Formosa’s Byqlovi in US Market

Fineline Cube Jun 10, 2025

US-based ophthalmic pharmaceutical company Harrow (NASDAQ: HROW) announced a licensing agreement with Taiwan-based Formosa Pharmaceuticals...

Company Drug

FDA Approves Merck’s Enflonsia for Infant RSV Protection

Fineline Cube Jun 10, 2025

The US Food and Drug Administration (FDA) granted approval to Merck, Sharp & Dohme’s (MSD;...

Company Drug

Sino Biopharmaceutical Gains CDE Approval for TQC3721 COPD Trial

Fineline Cube Jun 10, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received approval from the Center...

Company Drug

Huadong Medicine’s HDM1010 Gets FDA Nod for Phase I Trial in T2D

Fineline Cube Jun 10, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received approval from the...

Company Deals

Sanyou Biopharma Partners with Medicovestor to Advance Next-Gen ADCs

Fineline Cube Jun 10, 2025

China-based Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. announced a strategic partnership with US-headquartered Medicovestor, Inc. to...

Posts pagination

1 … 121 122 123 … 640

Recent updates

  • Zhifei Bio Initiates Phase I Study for DTaP-Hib Quadrivalent Vaccine – Component Combination Targets Pediatric Immunization Compliance
  • Changchun High-Tech Wins FDA Orphan Drug Designation for GenSci128 – TP53 Y220C Reactivator Targets Gastric Cancer
  • China NHC Elevates Chikungunya and SFTS to Category B Status – Enhanced Surveillance and Control Measures Effective April 2026
  • Gan & Lee’s Bonfaglutide Wins NMPA Approval for OSA Study – Biweekly GLP‑1 Expands to Sleep Apnea Indication
  • Clover Bio Reports Positive SCB‑1019 Phase I Data – RSV PreF Vaccine Demonstrates Superior Booster Response vs. GSK’s Arexvy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Zhifei Bio Initiates Phase I Study for DTaP-Hib Quadrivalent Vaccine – Component Combination Targets Pediatric Immunization Compliance

Company Drug

Changchun High-Tech Wins FDA Orphan Drug Designation for GenSci128 – TP53 Y220C Reactivator Targets Gastric Cancer

Policy / Regulatory

China NHC Elevates Chikungunya and SFTS to Category B Status – Enhanced Surveillance and Control Measures Effective April 2026

Company Drug

Gan & Lee’s Bonfaglutide Wins NMPA Approval for OSA Study – Biweekly GLP‑1 Expands to Sleep Apnea Indication

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.